jeu. déc. 10, 2009 5:45 am
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia.
Tasigna surpassed Glivec in every measure of treatment efficacy designated in the trial including prevention of disease progression at 12 months[1]
. At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400 mg once daily[1]
. Tasigna was well tolerated; few patients receiving 300 mg twice daily discontinued because of adverse events[1]
. Results support Tasigna as treatment in newly diagnosed patients with Ph+ CML; Novartis to file worldwide applications
Extrait de http://insciences.org/article.php?article_id=7879